echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > All you want to know about bevacizumab is here

    All you want to know about bevacizumab is here

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.
    supply of oxygen, oxygen, and other nutrients, thereby inhibiting tumor cell growth

    .
    Bevacizumab was approved by the U.
    S.
    Food and Drug
    Administration in 2004 and was approved to enter the Chinese market in 2010
    .
    As one of the important drugs against tumor angiogenesis, bevacizumab has been used in the treatment of various malignant tumors

    .

    Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.
    supply of oxygen, oxygen, and other nutrients, thereby inhibiting tumor cell growth

    .
    Bevacizumab was approved by the U.
    S.
    Food and Drug
    Administration in 2004 and was approved to enter the Chinese market in 2010
    .
    As one of the important drugs against tumor angiogenesis, bevacizumab has been used in the treatment of various malignant tumors

    .
    Vascular management

     

    1.
    Applicable diseases  

    1.
    Applicable diseases  
    1.
    Applicable diseases  

     

    • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
      .

       

    • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
      .

  • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
    .

     

  • Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
    .

    Domestic Medical Insurance Indication Domestic Medical Insurance Indication : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
    .
    metastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
    .
    colorectal cancer lung cancer

     

  • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
    .

  • Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
    .

    Domestic label indications Domestic label indications : including four major medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, refractory, recurrent or metastatic cervical cancer
    .
    Including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, refractory, recurrent or metastatic cervical cancer
    .
    In addition to the above six indications, bevacizumab can also be used for metastatic renal cancer, advanced metastatic breast cancer , radiation brain injury, pleural effusion, ascites and other indications (applicable abroad) .
    Metastatic renal cancer, advanced metastatic breast cancer , radiation brain injury, pleural effusion, ascites and other indications (applicable abroad) Breast cancer 2.
    Dosage
    2.
    Dosage
    3.
    Adverse reactions and treatment methods
    3.
    Adverse reactions and treatment methods
    4, toxicology study 4, toxicology study 5, drug interaction 5, drug interaction and sunitinib combination may cause the risk of microvascular hemolytic anemia .
    Sunitinib 6.
    Frequently Asked Questions
    6.
    Frequently Asked Questions (1) About the treatment of
    hypertension during bevacizumab treatment .
    (1) About hypertension during bevacizumab administration
     
        
      
    problem handling
    .
    Hypertension Hypertension is the most common adverse reaction during bevacizumab administration, which can be handled by referring to the following management procedures (Figure 1) .
    Hypertension is the most common adverse reaction during bevacizumab administration, which can be handled by referring to the following management procedures (Figure 1) .
    If blood pressure is greater than 160/100mmHg, bevacizumab should be suspended, drug intervention is recommended, and the following management steps should be followed (Figure 2) .
    Blood pressure should be re-measured for at least 2 weeks after each additional drug
    .
    (Note: CYP3A4 inhibitors such as verapamil and diltiazem may interact with bevacizumab and affect the efficacy, so it is not recommended .
    )
    If blood pressure is >160/100mmHg, the use of bevacizumab should be suspended, it is recommended For drug intervention, follow the following management steps for intervention treatment (Figure 2) , and blood pressure should be re-measured for at least 2 weeks after each additional drug .
    Figure 1 Flow chart of blood pressure (mmHg) management during bevacizumab treatment (source reference [1] [1] )
     




     

     

    Figure 2 Treatment steps for patients taking antihypertensive drugs for the first time (source reference [1] [1] ) (2) The question of whether bevacizumab can be used for cancer maintenance therapy .
    (2) Questions about whether bevacizumab can be used for cancer maintenance therapy .
    Clinical studies have shown that maintenance therapy with bevacizumab alone or in combination with other chemotherapy drugs can effectively improve PFS and OS in advanced non-small cell lung cancer, advanced ovarian cancer , metastatic colorectal cancer, advanced breast cancer, etc.
    It is recommended that clinicians fully Weigh the patient's clinical benefits, adverse reactions,
    quality of life and economic situation, and adjust the treatment plan in a timely manner according to the principle of individualization .
    Quality of life in ovarian cancer (3) Concerning the safety of minor surgery during bevacizumab administration .
    (3) Concerning the safety of minor surgery during bevacizumab administration .
    Foreign studies have shown that if minor surgery (including central venous catheterization/catheter removal, thoracic drainage, oral surgery, biopsy, etc.
    ) is required during bevacizumab administration, 16-17 days of drug withdrawal may be required before surgery Transition, if bevacizumab treatment is continued after surgery, a 9-14 day surgical recovery period is required
    .
    References: [1] Tang Xinying, Kuang Zemin.
    Expert
    consensus on blood pressure management in ovarian and cervical cancer patients treated with bevacizumab : Interpretation of British expert recommendations in 2019.
    Rational Drug Use in China, 2020; 1: 11-15.
    Consensus interpret
     

     
     

     


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.